Global Leader in Women’s Health to Present Research and Educational Opportunities Focused on Improving Workflow and Efficiency

Hologic, Inc. (Nasdaq: HOLX) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology (ECR) in Vienna, Austria from February 28 to March 2.

The pioneer behind 3D mammography, Hologic will present new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists. Presented by esteemed breast imaging specialist and study author Dr. Sarah M. Friedewald, Associate Professor of Radiology and Chief of Breast Imaging at Northwestern Memorial Hospital, the research shows that Hologic’s Genius AI® Detection solution has an exceptional ability to correctly match pairs of Regions of Interest (ROIs) in different views.¹

“These data reveal how AI can help us correlate ROIs in a way that we have never seen before, which underscores that deep-learning technology can supplement our workflow as radiologists and help us provide better patient care,” said Dr. Friedewald. “Beyond its impact on our daily practices, these data emphasize the transformative potential AI has to drive improvements across the breast health spectrum. I’m looking forward to sharing this information with my colleagues from around the globe at ECR.”

In addition, Dr. Friedewald will also present research highlighting how the Genius AI Detection algorithm can help radiologists identify potential cancers on mammograms previously interpreted as normal.² In a third study, research will be presented that demonstrates Hologic’s deep learning-based AI algorithm can help significantly enhance performance, surpassing traditional machine learning Computer-Aided Detection (CAD) algorithms in specificity and overall effectiveness.³

“Research and education are central tenets of Hologic’s innovation, to support radiologists in achieving better patient outcomes,” said Tanja Brycker, Vice President, Strategic Development, Breast & Skeletal Health and Gynecological Surgical Solutions at Hologic. “We’re excited to present groundbreaking research at ECR and to continue our collaboration with Bayer on contrast-enhanced mammography. By offering our customers the opportunity to engage with world-renowned experts and explore our latest technology, we are ensuring they feel confident in their patient care procedures and decisions.”

Hologic and Bayer will co-sponsor a contrast-enhanced mammography (CEM) symposium, facilitated by globally recognized breast imaging radiologists Dr. Jacopo Nori, Chief of Breast Imaging at Careggi University Hospital in Florence, Italy, and Dr. Marc Lobbes, Chairperson of the Board, Department of Medical Imaging at Zuyderland Medical Center in Sittard-Geleen, the Netherlands.

The symposium, which will take place on Thursday, February 29 at 11 a.m. CET, is designed to provide radiologists with an understanding of how CEM can be effectively implemented into their daily practice.

Hologic’s Genius AI® Detection technology is a cutting-edge solution now commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024.

About Hologic, Inc.

Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data framework for improving women’s well-being.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.

Hologic, The Science of Sure and Genius AI are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of Hologic. Dr. Sarah M. Friedewald is a paid Hologic consultant.

Source: Hologic, Inc.

____________________
¹		Correlating breast lesions in tomosynthesis CC and MLO views using artificial intelligence (AI). Authors: Sarah Friedewald (Northwestern), Chirag Phargi (Solis). Accepted as podium presentation.
²		Evaluating performance of an artificial intelligence (AI) detection system on prior screening tomosynthesis studies of breast cancer patients. Authors: Sarah Friedewald (Northwestern), Chirag Phargi (Solis). Accepted as podium presentation.
³		Performance of a traditional machine learning computer-aided detection (CADe) algorithm versus a deep learning artificial intelligence (AI) algorithm on digital breast tomosynthesis (DBT) studies. Authors: Manisha Bahl (MGH), Constance Lehman (MGH). Accepted as electronic poster.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227246191/en/

Media Contact
Bridget Perry
Director, Corporate Communications
+1 508.263.8654
bridget.perry@hologic.com

Investor Contact
Ryan M. Simon
Vice President, Investor Relations
+1 858.410.8514
ryan.simon@hologic.com

Logo

Tags

More Like This

United Imaging Intelligence Unveiled Next-Generation Radiology Solutions at ECR 2024

United Imaging Showcases AI-Driven Innovations and Expands European Presence at ECR 2024

Diana Bracco: "Artificial Intelligence will assist radiologists in making increasingly accurate and reliable diagnoses"

ConcertAI's TeraRecon Launches Three New Care Suites, Life Sciences Platform, and Strategic Partnerships at #ECR24

New technology aiming to improve patients' outcomes in breast cancer

ScreenPoint Medical Showcases Transpara® Breast AI Designed to Improve Cancer Detection and Support Single Reader Screening at ECR

b-rayZ Secures CE Mark for Industry-First Custom AI Technology, Revolutionizing End-to-End Breast Diagnostics

mediaire transforms radiology with AI, securing a European €12 million investment to fuel global growth